Inicio › Linfoma difuso de células B grandes › Massachusetts › Boston
Ensayos clínicos de Linfoma difuso de células B grandes en Boston, MA
16 estudios para Linfoma difuso de células B grandes buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
ReclutandoFase 3
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
ReclutandoFase 2
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
ReclutandoFase 1/2
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
ReclutandoFase 2
- Boston Medical Center, Boston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
ReclutandoEstudio observacional
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
ReclutandoFase 1
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ensayos de Linfoma difuso de células B grandes en otras ciudades
- New York City, NY21 estudios
- Baldwin Park, CA19 estudios
- Chicago, IL18 estudios
- Los Angeles, CA17 estudios
- Houston, TX17 estudios
- Milwaukee, WI16 estudios
- Portland, OR15 estudios
- Philadelphia, PA15 estudios
- Nashville, TN14 estudios
- Durham, NC14 estudios
- Dallas, TX13 estudios
- Washington, DC12 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer de pulmón de células no pequeñas89 estudios
- Cáncer (todos los tipos)86 estudios
- Cáncer del colon y del recto63 estudios
- Cáncer metastásico63 estudios
- Cáncer de ovario62 estudios
- Cáncer de pulmón62 estudios
- Cáncer de próstata61 estudios
- Depresión51 estudios
- Cáncer de endometrio50 estudios
- Leucemia mielógena aguda45 estudios
- Cáncer de páncreas44 estudios
De ClinicalTrials.gov, datos obtenidos el 29 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.